Basit öğe kaydını göster

dc.contributor.authorKose, Engin
dc.contributor.authorUnal, Ozlem
dc.contributor.authorBulbul, Selda
dc.contributor.authorGunduz, Mehmet
dc.contributor.authorHaeberle, Johannes
dc.contributor.authorArslan, Nur
dc.date.accessioned2020-06-25T18:22:51Z
dc.date.available2020-06-25T18:22:51Z
dc.date.issued2017
dc.identifier.citationclosedAccessen_US
dc.identifier.issn0009-9120
dc.identifier.issn1873-2933
dc.identifier.urihttps://doi.org/10.1016/j.clinbiochem.2017.01.011
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6932
dc.descriptionHaberle, Johannes/0000-0003-0635-091Xen_US
dc.descriptionWOS: 000406086600009en_US
dc.descriptionPubMed: 28132756en_US
dc.description.abstractObjectives: Citrullinemia type 1 (CTLN1) is an autosomal recessive genetic disorder caused by mutations in the argininosuccinate synthetase 1 (ASST) gene, which encodes for the argininosuccinate synthetase enzyme. Here, we report genetic and clinical characterizations of 14 patients with citrullinemia type 1. Design & methods: The study group consisted of 14 patients (4 females, 10 males) diagnosed with citrullinemia type 1 from three centers in Turkey. Age of onset, clinical presentation, initial citrulline and ammonia levels, family history and molecular genetic analysis were retrospectively evaluated. Results: The mean age of the cohort and the mean age at the time of diagnosis were 483 +/- 36.5 months (min: 12 days, max: 10 years) and 11.6 +/- 26.2 months (min: 3 days, max: 8 years), respectively. In four patients, a homozygous p.Gly390Arg pathogenic variant was detected. All patients homozygous for p.Gly390Arg were diagnosed during the newborn period with the clinical presentation of classical citrullinemia. In each two patients, homozygous p.Arg86His, c.773 + 49C>T and p.Gly362Val pathogenic variants were detected. Clinical presentation was compatible with the mild form of the disease in patients homozygous for c.773 + 49C>T and for Gly362Val. Novel compound heterozygous genotypes (p.A1a164Pro/p.Gly390Arg; p.Leu290Pro/p.Gly390Arg; p.Thr389Pro/p.Gly390Arg) were identified in five patients. Of these, three siblings with CTLN1 were diagnosed with the compound heterozygous genotype p.A1a164Pro/p.Gly390Arg at the age of 4 days, 5 days and 2 years, respectively. The other two patients with novel compound heterozygous genotypes (p.Leu290Pro/p.Gly390Arg; p.Thr389Pro/p.Gly390Arg) were identified in the first month of life as neonatal onset form and were born to non-consanguineous parents. Conclusion: In our study, consistent with the literature, a correlation was found between homozygous p.Gly390Arg mutation and the classic neonatal onset form. Mild citrullinemia was detected in patients with c.773 + 49C>T or p.Gly362Val pathogenic variants. This study adds to our understanding of the molecular genetic background of patients with CTLN1, and allows to infer on the correlation between the genotype and phenotype of the disease. (C) 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.en_US
dc.description.sponsorshipSwiss National Science FoundationSwiss National Science Foundation (SNSF) [310030_153196]en_US
dc.description.sponsorshipThe study on urea cycle disorders is supported by the Swiss National Science Foundation (grant 310030_153196 to JH).en_US
dc.language.isoengen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.isversionof10.1016/j.clinbiochem.2017.01.011en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleIdentification of three novel mutations in fourteen patients with citrullinemia type 1en_US
dc.typearticleen_US
dc.contributor.departmentKırıkkale Üniversitesien_US
dc.identifier.volume50en_US
dc.identifier.issue12en_US
dc.identifier.startpage686en_US
dc.identifier.endpage689en_US
dc.relation.journalClinical Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster